eef-2 Antibody

What is eEF2 and what cellular functions does it perform?

eEF2 (Elongation Factor 2) catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this process, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. eEF2 orchestrates the coordinated movement of the two tRNA molecules, the mRNA, and conformational changes in the ribosome . This function is essential for efficient protein synthesis across eukaryotic organisms.

What types of eEF2 antibodies are available for research?

Research-grade eEF2 antibodies are available in multiple formats:

• Rabbit Polyclonal Antibodies - Generated against specific peptide regions (e.g., within Human eEF2 aa 800 to C-terminus)

• Rabbit Recombinant Monoclonal Antibodies - Such as the EP880Y clone with high specificity and reproducibility

• Species-specific antibodies - Such as those specific for Saccharomyces cerevisiae eEF2 that don't cross-react with human eEF2

What applications are eEF2 antibodies validated for?

How should I design experiments to study eEF2's role in translation elongation?

When designing experiments to study eEF2's function in translation elongation, consider a multi-method approach:

• Antibody selection: Choose antibodies that specifically recognize phosphorylated and non-phosphorylated forms of eEF2 to distinguish between active and inactive states

• Translation assays: Implement ribosome transit assays in conjunction with eEF2 detection to correlate protein levels with translational activity

• Knockout/knockdown validation: When using genetic models with reduced eEF2 levels (like heterozygous models), validate protein reduction with Western blot using calibrated loading controls and quantify the degree of reduction (typically ~30% in PFC tissues of heterozygous models)

• Cell-type specificity: Since eEF2 is differentially expressed between excitatory and inhibitory neurons, use co-immunostaining with CaMKIIα (excitatory neuron marker) and GAD65/67 (inhibitory neuron markers) to determine cell-type specific effects

What controls are essential when using eEF2 antibodies in neurological research?

When studying eEF2 in neurological contexts, the following controls are critical:

• Tissue-specific expression validation: eEF2 protein levels vary significantly between brain regions despite similar mRNA levels (e.g., 30% reduction in prefrontal cortex but minimal changes in striatum of heterozygous models)

• Cell-type controls: Include co-localization studies with neuronal vs. glial markers, and excitatory vs. inhibitory neuron markers as eEF2 has significantly higher expression in excitatory neurons than inhibitory neurons

• Knockout/knockdown validation: Partial knockdown through shRNA can serve as an antibody specificity control

• Loading controls: Given the high abundance of eEF2, traditional loading controls should be carefully selected and validated

• Negative controls: When using S. cerevisiae-specific antibodies, human samples can serve as negative controls due to the lack of cross-reactivity

How should I optimize Western blotting conditions for eEF2 detection?

For optimal Western blot detection of eEF2:

• Dilution optimization:

  • For recombinant monoclonal antibodies (e.g., EP880Y): Use extreme dilutions (1:100,000) due to high affinity and abundant target

  • For polyclonal anti-yeast eEF2: Use 1:10,000 dilution

• Sample preparation:

  • For brain tissue: Prepare separate fractions (total homogenate, synaptosome) to detect compartment-specific changes

  • For cell lines: 20 μg of whole cell lysate is typically sufficient (e.g., C6, PC-12, NIH/3T3 cell lines)

• Detection systems:

  • Use highly sensitive chemiluminescence systems to accommodate high dilution factors

  • Consider fluorescent secondary antibodies for multiplexing with other translation factors

What methodology should I use to study newly synthesized proteins dependent on eEF2 activity?

To study newly synthesized proteins dependent on eEF2:

• SUnSET (Surface Sensing of Translation) technique: Pulse cells with puromycin to label newly synthesized proteins, then detect with anti-puromycin antibodies alongside eEF2 detection

• AHA labeling methodology:

  • Incorporate the methionine analog azidohomoalanine (AHA) as a non-canonical amino acid

  • Click chemistry can then be performed to visualize newly synthesized proteins

  • This approach has demonstrated reduction in protein synthesis in CaMKIIα-positive excitatory neurons in eEF2 heterozygous models

• Specific protein synthesis measurement:

  • For targeted proteins like GluA2, combine AHA labeling with immunoprecipitation

  • This approach revealed a remarkable decline in newly synthesized GluA2 protein in eEF2 knockdown neurons

How do I interpret changes in eEF2 levels in relation to neurological function?

When interpreting eEF2 level changes in neurological contexts:

• Region-specific effects: eEF2 reduction may have differential impacts across brain regions - significant functional consequences in prefrontal cortex with minimal effects in other cortical regions or striatum

• Synaptic function correlation:

  • ~30% reduction in eEF2 correlates with reduced spine density in PFC

  • Decreased excitability and impaired AMPAR-mediated synaptic transmission in Layer 5 neurons of medial PFC

• Behavioral implications:

  • Reduced eEF2 in prefrontal cortex is associated with social behavior deficits and elevated anxiety

  • Specifically, eEF2 knockdown in excitatory neurons of medial PFC impairs social novelty preference

• Therapeutic potential:

  • AMPAR potentiators (e.g., PF-4778574) can correct social novelty deficits in eEF2-deficient models

  • Chemogenetic activation of excitatory neurons in mPFC also rescues behavioral deficits

How can I differentiate between eEF2 and eEF2K effects in my research data?

Distinguishing between eEF2 and eEF2K (its kinase) effects requires careful experimental design:

What are potential reasons for inconsistent eEF2 antibody staining in brain tissue sections?

Inconsistent eEF2 antibody staining in brain tissues may result from:

• Region-specific expression: eEF2 has differential expression across brain regions despite similar mRNA levels

• Cell-type variability: Higher expression in excitatory neurons (CaMKIIα-positive) than inhibitory neurons (GAD65/67-positive)

• Fixation sensitivity: Prolonged fixation may mask epitopes, particularly for antibodies targeting the C-terminus

• Antibody specificity issues: Verify specificity with appropriate controls:

  • Test in knockout/knockdown tissues

  • Confirm with alternative antibody clones

  • Pre-adsorption with immunizing peptide

• Developmental changes: eEF2 expression patterns may vary with developmental stage, particularly in embryonic vs. adult tissue

How can I address weak signal issues when detecting eEF2 in protein synthesis studies?

For weak signal issues in eEF2-related protein synthesis studies:

• Optimize AHA incubation:

  • Methionine-free pre-incubation time: 30-60 minutes

  • AHA concentration: 50-100 μM

  • Incubation duration: 1-4 hours depending on cell type

• Signal amplification strategies:

  • For GluA2 synthesis studies, combine AHA labeling with biotin-based detection

  • Use tyramide signal amplification for immunohistochemistry applications

• Background reduction:

  • Include protein synthesis inhibitors (cycloheximide, anisomycin) as negative controls

  • Perform parallel detection of housekeeping proteins to normalize translation efficiency

• Application-specific optimization:

  • For cortical neuron cultures infected with eEF2 shRNA-expressing lentivirus, extended AHA incubation (2-4 hours) may be necessary to detect subtle changes in GluA2 synthesis

What are promising research avenues for eEF2 antibodies in neurodegenerative disease studies?

Future research with eEF2 antibodies in neurodegenerative contexts should consider:

• Opposing roles of eEF2 and eEF2K:

  • eEF2K activity increases in neurodegenerative conditions

  • eEF2K deletion or inhibition enhances cognition in Alzheimer's and Parkinson's disease models

  • eEF2 activation may have protective effects against neurodegeneration

• Excitatory/inhibitory balance:

  • Given eEF2's higher expression in excitatory neurons, investigate its contribution to E/I imbalance in autism spectrum disorders

  • Use co-labeling with CaMKIIα and GAD65/67 to track cell-type specific changes

• Proteome-wide effects:

  • Apply eEF2 antibodies with BONCAT (bio-orthogonal non-canonical amino acid tagging) to identify newly synthesized proteins affected by eEF2 deficiency

  • GSEA (Gene Set Enrichment Analysis) showed mitochondrial translation, actin binding, and cell adhesion proteins are significantly affected by eEF2 reduction

• Autism-associated protein connections:

  • eEF2 reduction affects levels of autism-associated proteins including FMR1, ELMO1, and CYFIP1 in synaptosomal fractions

  • These connections warrant further investigation in autism models